FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi - STAT

FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi - STAT

FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi

By KATE SHERIDAN

ALNYLAM PHARMACEUTICALS

The FDA has approved the second-ever drug based on a Nobel prize-winning technique known as RNA interference, Alnylam’s givosiran. 

READ MORE